| Literature DB >> 26827690 |
Chiara Ciccarese1, Matteo Santoni2, Matteo Brunelli3, Sebastiano Buti4, Alessandra Modena1, Massimo Nabissi5, Walter Artibani6, Guido Martignoni3, Rodolfo Montironi7, Giampaolo Tortora1, Francesco Massari8.
Abstract
The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next-generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic efficacy for many patients. Several explanations for response and/or resistance to abiraterone acetate and enzalutamide are emerging, but growing interest is focusing on importance of AR splice variants (AR-Vs) and in particular of AR-V7. Increasing evidences highlight the concept that variant expression could be used as a potential predictive biomarker and a therapeutic target in advanced prostate cancer. Therefore, understanding the mechanisms of treatment resistance or sensitivity can help to achieve a more effective management of mCRPC, increasing clinical outcomes and representing a promising and engaging area of prostate cancer research.Entities:
Keywords: AR-V7; Androgen receptor; Anti-androgens sensitivity; Prognostic role; Prostate cancer; Splice variant; Taxane sensitivity
Mesh：
Substances：
Year: 2015 PMID： 26827690 DOI： 10.1016/j.ctrv.2015.12.003
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111